Article

Opthalmology Times, Digital Edition, September 15th, 2009

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
FDA grants Breakthrough Therapy Designation for Tinlarebant
May 21st 2025

FDA grants Breakthrough Therapy Designation for Tinlarebant

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Q&A: Kapil Mishra on radiation retinopathy in uveal melanoma
May 21st 2025

Q&A: Kapil Mishra on radiation retinopathy in uveal melanoma

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Viridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye disease
May 20th 2025

Viridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye disease

Kriya Therapeutics announces preclinical data for KRIYA-825, gene therapy injection for the treatment of GA
May 20th 2025

Kriya Therapeutics announces preclinical data for KRIYA-825, gene therapy injection for the treatment of GA

© 2025 MJH Life Sciences

All rights reserved.